PHARMA PATIENT ACCESS WORLD CONGRESS 2025 EUROPE
Improving Patient Access for Better Health Outcomes and Quality of Life
Copthorne Tara Hotel London Kensington, London, UK, London, United Kingdom
Wednesday 11th - Thursday 12th June 2025
Event Introduction
Dear Colleagues,
FACILITATE LIVE is very pleased to welcome you to our upcoming PHARMA PATIENT ACCESS World Congress 2025 Europe. The two-day Congress aims to build meaningful collaborations within the industry, advocacy groups, clinicians, researchers and most importantly, patients and their caregivers.
The congress focuses on “Improving Patient Access for Better Health Outcomes and Quality of Life.”
Massive investment and advances in research and development of novel therapeutics by Pharmaceutical and Biotechnology manufacturers, has resulted in the life science industry obtaining an accelerated rise in the number of drugs that have been brought to market over the past decade.
Pharma Patient Access, also known as market access, is a term that describes how pharmaceutical and biotech companies ensure that their products are accessible to patients. The primary goal is to ensure patients receive timely, consistent, and affordable access to care at prices that reflect extensive negotiations between payors and biopharma manufacturers. Patient access is also a crucial aspect of the healthcare system, as it affects the quality and availability of care for patients. Improving patient access can lead to better health outcomes and improved quality of life for patients.
It involves a variety of activities, including, Pharmaceutical companies negotiating with stakeholders in healthcare access. Companies have to demonstrate the clinical and economic value of their products. Companies need to analyze trial design and evaluate clinical trial outcomes. They also need to develop an understanding of the benefits for patients.
Innovative pricing agreements, also known as “risk sharing” or “rebate” schemes can be proposed by Pharmaceutical companies to help patients gain access to high cost drugs and treatments. These are designed to improve the cost-effectiveness of a medicine and allow health authorities to recommend treatments that might not otherwise be considered cost effective.
The industry has come a long way with utilising a patient-centred approach. When patients are involved in their treatment decisions, they are more likely to take their medication and see improved health outcomes.
Whilst the industry has advanced in recent years, the evolving healthcare model and ecosystem brought forward by advances in technology and more involved, empowered patients, means true Patient Access is a continuing quest and a compelling commitment.
We look forward to meeting you at the Congress!
Sincerely yours,
Jocelyn Raguindin
Conference Director
Paradigm Global Events / Facilitate Live
GAIN THE LATEST INSIGHT
- What does patient access mean for the pharmaceutical and life science industry?
- Patient access strategies that can lead to better health outcomes and quality of life for patients.
- Ensuring that patients receive the care they need when they need it.
- Successful strategies and best practices to successfully manage patients access in healthcare
- How to develop and execute a strategy to improve patient engagement?
- Recognizing the regulatory and clinical development framework for Patient Access
- Understanding the barriers to patient access and addressing them accordingly.
- How to predict potential barriers to launch and make plans to overcome them.
- How Pharmaceutical companies can prioritize access at every stage of the drug development process to ensure that their products reach the patients who need them most.
- Hear an overview of the market access system in place in large pharma markets
- Gain knowledge of the Market Access environment in Europe’s major markets
- A standardized and transparent process to improve the efficiency of the pharmaceutical system.
- Reducing health disparities by ensuring that everyone can receive the care they need, regardless of their socioeconomic status, geographic location, or cultural background
- How to maintain mutually beneficial ongoing partnerships between the patients and industry?
- Know how to implement a successful market access strategy and how to communicate value to stakeholders
- Hear an overview of the market access system in place in large pharma markets
- Gain knowledge of the Market Access environment in Europe’s major markets
- Global and European MA trends,
- Payer & industry perspective for better Patient access
WHO SHOULD ATTEND?
This Congress is beneficial to patients, pharmaceutical, biotech companies, researchers, physicians, patient advocacy groups, regulatory agencies, technology and healthcare companies.
Network with members of the boards, VP’s, Directors, Heads/Chiefs and Senior Managers and thought leaders involved in:
- Patient Access
- Patient Advocacy
- Patient Engagement
- Patient Support Strategy & Insights
- Equity, Diversity and Inclusion
- Patient Outcomes
- Medical Affairs
- Commercialisation
- Market Access
- Health Economics and Outcomes Research
- Regulatory Affairs and Policy
- Clinical Research and Development
- RWE, and Data Management
- Data Science, Technologies and Analytics
- Technology Science and Development
- Clinical Trials Management
- Payer Relationship Management
- Drug Pricing
- Reimbursement
- Health Technology Assessment
- Product and Value Strategy
- Quality and Compliance
- Epidemiology
- Programme Management
- Supply Chain Management
- Digital Patient Experience
- Digital Technologies
- Wearables
- Clinical Operations
- Clinical Insights and Experience
- Site Collaborations and Management
- Patient Diagnosis
- Pharmacy
- Business Development
TRENDS & STRATEGIES IN PATIENT ACCESS
- Ensuring that patients can access products in a timely and affordable manner.
- Need to have access to data and insights early and often to make informed decisions about how pharma and biotech companies get their drugs to patients
- Digitizing healthcare to improve patient access
- Demonstrating cost-effectiveness of the product
- What is most important to patients?
Moderator:
Panelists:
- Addressing the shifting regulations
- Payer revenue optimization strategies
- The need for a 360-degree perspective across the drug development life cycle,
- The promise of real-world data (RWD) to address complex challenges
- How can we seize this opportunity to improve patient access to medicines?
- Assessing the impact of the regulation on national HTAs
- Strategic implications for health technology developers
- Its influence on price and reimbursement negotiations.
- Meeting growing demands for rigorous data requirements
- Understanding of increasingly diverse environment
- Strategic and adaptive approach in navigating complexities of different ecosystem
- Breaking down silo mentality
- Harmonizing access needs and aligning strategies at an early stage
- Advancing landscape and drivers in medical devices
- The importance of early and continuous stakeholder engagement
- How multi-stakeholder collaboration streamlines the path to market and guarantees that medical devices are thoroughly designed, tested, and deployed.
- Significance of patient-centered design on market access
- Prioritizing patient needs and preferences to enhance patient outcomes
- Adopting tech-powered tools that enables to have a more direct relationship with HCPs and the patients they serve
- Innovative technologies that make patient-focused approaches scalable and efficient
- Innovative steps to improve access strategy by interacting with PAGs
- Best practices while interacting with PAGs in order to guarantee efficient cooperation and patient needs alignment.
- Integrating patient insights to improve the acceptance and relevance of health innovations
- Overcoming challenges interacting with PAGs
REGULATORY & COMMERCIALISATION
- Key trends that will affect the European biopharmaceutical market access landscape
- Impact of both the EU’s industrial pharma policy and the health technology assessment (HTA) landscape
- Overcoming the increasing constraints on government healthcare budgets
- Fundamental policy changes affecting the industry
- Breaking down silos for comprehensive strategy to anticipate challenges and opportunities in both short and long term
- Addressing urgent policy changes and stakeholder concerns while planning for the future
- Integrating patient-centricity into the broader patient access strategy
- Harmonisation imperative for sustained growth
- Varying framework in place to improve patient access to innovative medicines
- Considerations for a suitable pharmaceutical regulatory and clinical framework
- How regulation can help to unlock the potential of innovative medicines
- Streamlined regulatory framework bringing breakthroughs to patients faster
- Improving provider schedules and allowing patients to schedule their own appointment to improve access and patient satisfaction.
- Using technology to improve care coordination
- Streamlining processes to reduce inefficiencies, delays and revenue loss
- Facilitating patient engagement with the use of patient portals, apps and educational resources
- Value-based approach to affordability
- Varying healthcare needs and affordability challenges
- Programmes that provide patients financial support to help fund therapy expenditures
- Significant pitfalls associated with programmes design
- Addressing the payer activation and reimbursement challenges
- The impact of regulatory roadblocks and competition
- Overcoming the issue on inadequate market adoption by HCPs
- Patient engagement and adoption challenges
- Encourage shared decision-making to help patients feel more empowered and make informed choices.
- Open and clear communication between patients and providers to build trust and understanding.
- Educate patients to ensure patients understand their treatment plan, medications, and diagnosis
- Use innovative technology to improve the patient experience
- Ensuring that patients have access to the right treatments at the right time and fair price that aligns with the effectiveness of a drug in treating disease
- Establishing pricing and reimbursement sustainability for both the pharmaceutical manufacturer and the healthcare payer
- Incorporating patient input to ensure that their drugs address the specific needs, preferences, and quality of life concerns of patients.
- Collaborative, patient-centric care approach that enhances the quality of life for patients with complex chronic conditions
- Removing barriers to treatment and improving patient access to essential therapies.
CHALLENGES & OPPORTUNITIES
- Understand the cause of health inequalities and how they affect the community
- Causes of health inequalities
- How do health inequalities impact health and wellbeing?
- How companies can address health equity through people and patient engagement;
- Success measures of efforts to advance health equity
- What can the industry do to promote health equity in the future?
Moderator:
Panelists:
- Structural interventions that have yielded health benefits
- Challenges and opportunities to advance improvements in minority health
- Recommendations to encourage the development of structural interventions likely to advance health disparities research
- Acquiring good quality data is essential in providing insights that can bring about improvement and reduce disparities
- Focussing on implementation, impact and evaluation
- Areas of focus for patient advocacy partnerships
- Best practice in working together to produce better outcomes for patients
- Benefits of working together
- Embracing a patient-centric mindset and keep the patient front of mind
- How to interact in every way with the groups that represent those patients
- Discover how telehealth can make healthcare more accessible
- Understanding patient perspectives on telemedicine crucial for its adoption and efficacy.
- Key recommendations for telemedicine optimization and equity
- Continuous evaluation and adaptation essential to address technological challenges and disparities in telehealth usage
- Using artificial intelligence (AI) to address barriers to Patient Access
- How can data and AI be utilised to promote access?
- How can AI tools make it easier and more affordable for patients to receive needed care?
- Potential to revolutionise the healthcare industry further
- Importance of early consideration and integration of RWE into market access and commercialization strategies
- How and where to access real-world Data?
- Leveraging existing data sources and technologies to enhance study quality and streamline processes
- Robust planning and interpretation methods for effective utilisation of data for driving evidence-based decision making
- Primary barriers why patients struggle to access the therapies they need
- Proactive steps life sciences companies can take to address these barriers
- Impact of Not overcoming Patient Access hurdles
- What Is pharma value and what should you know about it?
- Benefits of payer value proposition
- How to design an equitable value prepositions?
- Examples of Payer Value Proposition in Pharma
- Recommendations to enhance value assessment and recognition
- Strategies to improve implementation
- Optimising the benefits of value-based pricing, through complementary tools
- Understanding the intricacies of pharma reimbursement
- Reimbursement hurdles that impact market access of launching new therapies and patient access
- The impact of Health Technology Assessment in reimbursement
- A successful pharma reimbursement strategy
- Future trends in reimbursement
- Addressing the unequal access to medicines for patients across Europe
- Disparities in the time it takes for European patients to access new medicines persist
- Factors causing delays and barriers to access
- Stakeholders collaboration towards pragmatic solutions that work for patients and help address Europe’s health inequalities.
Moderator:
Panelists:
- Robust market access strategy to help ensure that pharmaceutical innovations benefit the widest population possible
- Rigorous, proactive methodologies to support reimbursement
- Effective approach guided by patient-centricity to ensure patients receive timely treatment.
- Continuous medical education resulting in better clinical outcomes for patients and improved physician performance
Moderator:
Panelists: